Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
Academic Article
Overview
MeSH Major
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Genes, erbB-1
Lung Neoplasms
Quinazolines
abstract
The presence of sensitizing EGFR mutations correlates with radiographic response. A short course of preoperative treatment serves a platform for evaluating activity of new agents and assures sufficient tumor availability for correlative analyses.
